Predicting steroid response in acute alcohol-associated hepatitis: Beyond biomarkers of alcohol consumption

Acute alcohol-associated hepatitis (AAH) is a life-threatening condition with high mortality, and steroid therapy remains the mainstay of treatment despite variable efficacy. The study by Sabatose et al explores patient factors distinguishing responders and non-responders to steroid therapy for AAH, focusing on phosphatidylethanol (PEth)-a biomarker of alcohol consumption-and other clinical variables. Their findings indicate that PEth, abstinence duration, and pre-treatment alcohol intake do not predict steroid response, while older age, lower pre-steroid albumin, and higher pre-steroid bilirubin are associated with non-response. Non-responders exhibit higher mortality and healthcare costs, underscoring the need for early identification to guide liver transplantation referrals. This commentary evaluates the implications of these findings-specifically, how prioritizing pre-steroid albumin, bilirubin, and age over alcohol biomarkers can improve clinical decision-making by reducing unnecessary steroid exposure and expediting transplantation referrals for high-risk non-responders-contextualizes them within existing literature, and highlights directions for future research to optimize AAH management.